Core Viewpoint - Avenue Therapeutics has announced the acquisition of its subsidiary Baergic Bio by Axsome Therapeutics, which includes the global rights to BAER-101, a novel therapy for epilepsy, potentially enhancing treatment options in a field with high unmet needs [1][2][7]. Company Overview - Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing therapies for neurologic diseases, headquartered in Miami, FL, and founded by Fortress Biotech, Inc. [5]. Transaction Details - The acquisition involves Axsome obtaining worldwide commercial, development, and manufacturing rights to BAER-101, with Baergic shareholders eligible for up to approximately $82 million in potential payments, including a $0.3 million upfront payment and milestone payments based on development and sales achievements [1][7]. - Avenue expects to receive approximately 74% of all future payments and royalties under the agreement [7]. Product Information - BAER-101, now referred to as AXS-17 by Axsome, has shown a promising safety and tolerability profile in clinical studies involving over 700 patients and is being evaluated for its anti-convulsant effects in epilepsy [3][2].

Core Points - The legal opinion letter confirms the legality of the 2024 annual general meeting of Dize (Jiangsu) Pharmaceutical Co., Ltd. [1][16] - The opinion is based on the review of relevant laws, regulations, and the company's articles of association [1][2] Group 1: Meeting Procedures - The notice for the 2024 annual general meeting was properly communicated to all shareholders, including details on time, location, and agenda [3][4] - The meeting was convened in accordance with the relevant legal and regulatory requirements [4][15] Group 2: Attendance and Qualifications - A total of 9 shareholders and their proxies attended the meeting, representing 178,558,990 shares, which is 38.87% of the total voting shares [4][6] - The qualifications of the attendees were verified, confirming their legitimacy to participate in the meeting [4][6] Group 3: Voting Procedures and Results - Voting was conducted through both on-site and online methods, with results being monitored and counted by designated personnel [6][15] - The voting results showed that 295,693,967 shares were in favor of the proposals, representing a significant majority of the votes cast [7][14]

Core Insights - Insmed Incorporated will present 11 abstracts from its respiratory portfolio at the ATS 2025 International Conference, focusing on the efficacy and safety of brensocatib and health outcomes in patients with Mycobacterium Avium Complex lung disease [1][2][26] Group 1: Company Overview - Insmed is a global biopharmaceutical company dedicated to developing first- and best-in-class therapies for serious diseases [1][26] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [26][27] Group 2: Research and Development - The Phase 3 ASPEN study is the largest clinical trial in bronchiectasis to date, evaluating brensocatib's performance across various patient subgroups [2][6] - New health economics and outcomes research related to MAC lung disease will also be presented, highlighting treatment patterns and health status improvements [1][3] Group 3: Upcoming Presentations - Presentations will include analyses of treatment patterns in non-cystic fibrosis bronchiectasis and healthcare resource utilization for MAC lung disease [3] - Specific sessions will focus on the efficacy of brensocatib in patients with different backgrounds, including those with eosinophilic bronchiectasis [3][9]